Deborah S. Jacobs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Deborah S. Jacobs has a total of 372 co-authors. Here are the top co-authors by number of shared publications:
Perry Rosenthal
Boston Eye Pain Foundation, Chestnut Hill, MA, USA
11 shared publicationsStephen C. Kaufman
7 shared publicationsHong-Gam Le
Boston Foundation for Sight, Needham, Massachusetts
6 shared publicationsKaren G. Carrasquillo
BostonSight, Needham, MA, USA
6 shared publications- Roni M. Shtein
Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, United States
6 shared publications W. Barry Lee
5 shared publications
Latest Publications
- 1 August 2026
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 52 (8) , 323
Introduction to Special Issue: Corneal Nerves and Neuropathies
- 1 August 2026
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 52 (8) , 323
Introduction to Special Issue: Corneal Nerves and Neuropathies
- 21 July 2026
- Published by Elsevier in Ophthalmology
- Vol. 133 (10) , 1280-1281
It’s Time to Split in Dry Eye Disease
- 21 July 2026
- Published by Elsevier in Ophthalmology
- Vol. 133 (10) , 1280-1281
It’s Time to Split in Dry Eye Disease
- 9 July 2026
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (12) , 1473-1474
Neurotrophic Keratopathy: The Need for Better Diagnostic Criteria
Was not provided for this article.
- 9 July 2026
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (12) , 1473-1474
Neurotrophic Keratopathy: The Need for Better Diagnostic Criteria
Was not provided for this article.
- 24 June 2026
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 52 (8) , 338-342
Ocular Neuropathic Pain: A Clinician's Approach
Ocular neuropathic pain (ONP) can be defined as “pain” or “discomfort” projected to eye because of a lesion or disease or physiological dysfunction of the nervous system. The diagnosis of ONP is a clinical one; history, eye examination, the anesthetic challenge, and in vivo confocal microscopy providing supportive roles in helping to distinguish nociceptive, nociplastic, and neuropathic pain. Multimodal treatment involving local agents and interventions, along with systemic agents, is often required.
- 24 June 2026
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 52 (8) , 338-342
Ocular Neuropathic Pain: A Clinician's Approach
Ocular neuropathic pain (ONP) can be defined as “pain” or “discomfort” projected to eye because of a lesion or disease or physiological dysfunction of the nervous system. The diagnosis of ONP is a clinical one; history, eye examination, the anesthetic challenge, and in vivo confocal microscopy providing supportive roles in helping to distinguish nociceptive, nociplastic, and neuropathic pain. Multimodal treatment involving local agents and interventions, along with systemic agents, is often required.
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2)
Nav1.8 Variant I206M as a Latent Susceptibility Factor in Postaxotomy Ocular Pain
A small proportion of patients develop persistent ocular pain after corneal refractive surgery, which injures the distal axons of trigeminal ganglia neurons innervating the eye. In this study, we investigate the role of a low-frequency Nav1.8 variant, c.618A > G (p.I206M), in the pathogenesis of persistent ocular pain after corneal refractive surgery. Whole-exome sequencing in a cohort of patients with post-LASIK ocular pain identified c.618A > G (p.I206M) in SCN10A. We characterized its functional effects using patch-clamp electrophysiology, computer simulations, and multielectrode array recordings of transfected rat trigeminal neurons. p.I206M produced a hyperpolarizing shift in activation of ∼5 mV without significant effects on current density, inactivation, persistent currents, or recovery kinetics. Modeling predicted a small increase in excitability, attenuated under simulated heterozygous conditions. MEA recordings indicated a significant increase in firing frequency in trigeminal neuron firing at 33 and 37°C for p.I206M vs reference (wild-type) neurons. Although subtle, the p.I206M activation shift may lower the excitability threshold of trigeminal neurons. In the context of axotomy-induced remodeling of the electrogenisome, such variants may act as latent susceptibility factors for chronic ocular pain. Together with prior findings of Nav1.7, TRPV1, and TRPM8 variants in this same cohort, these results support a multihit model, in which rare gain-of-function ion channel variants combine with nerve injury to drive persistent pain after injury, in this instance a second injury, to distal trigeminal axons. Given recent clinical validation of Nav1.8 as an analgesic target, this work further highlights the translational significance of Nav1.8 in human pain disorders.
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2)
Open AccessNav1.8 Variant I206M as a Latent Susceptibility Factor in Postaxotomy Ocular Pain
A small proportion of patients develop persistent ocular pain after corneal refractive surgery, which injures the distal axons of trigeminal ganglia neurons innervating the eye. In this study, we investigate the role of a low-frequency Nav1.8 variant, c.618A > G (p.I206M), in the pathogenesis of persistent ocular pain after corneal refractive surgery. Whole-exome sequencing in a cohort of patients with post-LASIK ocular pain identified c.618A > G (p.I206M) in SCN10A. We characterized its functional effects using patch-clamp electrophysiology, computer simulations, and multielectrode array recordings of transfected rat trigeminal neurons. p.I206M produced a hyperpolarizing shift in activation of ∼5 mV without significant effects on current density, inactivation, persistent currents, or recovery kinetics. Modeling predicted a small increase in excitability, attenuated under simulated heterozygous conditions. MEA recordings indicated a significant increase in firing frequency in trigeminal neuron firing at 33 and 37°C for p.I206M vs reference (wild-type) neurons. Although subtle, the p.I206M activation shift may lower the excitability threshold of trigeminal neurons. In the context of axotomy-induced remodeling of the electrogenisome, such variants may act as latent susceptibility factors for chronic ocular pain. Together with prior findings of Nav1.7, TRPV1, and TRPM8 variants in this same cohort, these results support a multihit model, in which rare gain-of-function ion channel variants combine with nerve injury to drive persistent pain after injury, in this instance a second injury, to distal trigeminal axons. Given recent clinical validation of Nav1.8 as an analgesic target, this work further highlights the translational significance of Nav1.8 in human pain disorders.
- 6 February 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 285, 144-151
Stromal Keratitis in the Zoster Eye Disease Study: Lessons Learned
- 6 February 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 285, 144-151
Stromal Keratitis in the Zoster Eye Disease Study: Lessons Learned
- 1 July 2025
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 51 (7) , 289
Introduction to Special Issue: Update on Ocular Surface Disease
- 1 July 2025
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 51 (7) , 289
Introduction to Special Issue: Update on Ocular Surface Disease
- 21 April 2025
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 36 (4) , 282-287
Scleral lenses for correction of irregular astigmatism: advances and limitations
Purpose of review: In this review, we will address advances and limitations in the field of scleral lenses pertaining to the correction of irregular astigmatism. Recent findings: There are reports on the benefits of scleral lenses for eyes with irregular astigmatism, particularly regarding improvement of visual acuity and the reduction of higher-order aberrations. Innovations such as wavefront-optimized and wavefront-guided optics can improve vision in keratoconus. Customized haptics, topographic and profilometric-based fitting, and impression-based design can achieve fit in problematic eyes with ectasia, after penetrating keratoplasty, and with corneal scarring. Challenges persist, including resource requirements for practitioners, patient difficulty with insertion and removal, and limitations to lens wear, including midday fogging and corneal edema. Risks such as graft failure persist. Summary: Scleral lenses have emerged as a useful tool in the management of irregular astigmatism, reducing the need for penetrating keratoplasty. By vaulting the cornea and resting on the sclera, scleral lenses neutralize corneal astigmatism, while providing a stable and comfortable surface for advanced optics. Over the past two decades, the use of scleral lenses has increased, reflecting advances in fitting systems, expanded access, greater adoption by clinicians, broader patient eligibility, and improved clinical outcomes.
- 21 April 2025
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 36 (4) , 282-287
Scleral lenses for correction of irregular astigmatism: advances and limitations
Purpose of review: In this review, we will address advances and limitations in the field of scleral lenses pertaining to the correction of irregular astigmatism. Recent findings: There are reports on the benefits of scleral lenses for eyes with irregular astigmatism, particularly regarding improvement of visual acuity and the reduction of higher-order aberrations. Innovations such as wavefront-optimized and wavefront-guided optics can improve vision in keratoconus. Customized haptics, topographic and profilometric-based fitting, and impression-based design can achieve fit in problematic eyes with ectasia, after penetrating keratoplasty, and with corneal scarring. Challenges persist, including resource requirements for practitioners, patient difficulty with insertion and removal, and limitations to lens wear, including midday fogging and corneal edema. Risks such as graft failure persist. Summary: Scleral lenses have emerged as a useful tool in the management of irregular astigmatism, reducing the need for penetrating keratoplasty. By vaulting the cornea and resting on the sclera, scleral lenses neutralize corneal astigmatism, while providing a stable and comfortable surface for advanced optics. Over the past two decades, the use of scleral lenses has increased, reflecting advances in fitting systems, expanded access, greater adoption by clinicians, broader patient eligibility, and improved clinical outcomes.
- 31 December 2024
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 51 (4) , 206-208
Drug Delivery in PROSE Device as Alternative to Frequent Drop Administration in Severe Ocular Surface Disease
The design of the prosthetic replacement of the ocular surface ecosystem (PROSE) device allows it to serve as a novel drug delivery system. In this article, we describe the off-label administration of amphotericin B and cenegermin by instillation in the PROSE device reservoir for the treatment of Candida keratitis in the setting of a persistent epithelial defect.
- 31 December 2024
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 51 (4) , 206-208
Drug Delivery in PROSE Device as Alternative to Frequent Drop Administration in Severe Ocular Surface Disease
The design of the prosthetic replacement of the ocular surface ecosystem (PROSE) device allows it to serve as a novel drug delivery system. In this article, we describe the off-label administration of amphotericin B and cenegermin by instillation in the PROSE device reservoir for the treatment of Candida keratitis in the setting of a persistent epithelial defect.
- 1 December 2024
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 50 (12) , 501
Eye & Contact Lens: Special 50th Anniversary Issue
- 1 December 2024
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 50 (12) , 501
Eye & Contact Lens: Special 50th Anniversary Issue